At ACADIA, we are dedicated to bringing innovative medicines to patients with neurological and related central nervous system (CNS) disorders. We are committed to partnerships and collaborations to expand access to our future products and to complement our portfolio of product candidates.
As part of our strategy, we selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In areas where our products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we plan to commercialize our product candidates in the United States. In therapeutic areas that require large specialty or primary care sales forces, we may choose to conduct commercialization through, or in collaboration with, partners. We plan to commercialize our products in markets outside of the United States on our own or by establishing strategic alliances.
We welcome the opportunity to learn more about how we can work together. To further explore partnering opportunities with ACADIA, please contact us.
ACADIA has formed two ongoing separate collaborations with Allergan focused in the areas of pain and ophthalmology:
The first collaboration has resulted in the discovery of alpha adrenergic drug candidates for the treatment of chronic pain.
In the second collaboration, Allergan and ACADIA are focused on the development and commercialization of selective muscarinic drugs for the treatment of glaucoma.